Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1928279 | 1.00 | USP2 (0.54) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL4079340 | 1.00 | USP2 (0.54) | USP2ALDH1A1LMNACYP1A2TSHR | |
| Hydrochloric Acid SCHEMBL9229306 | 0.97 | USP2 (0.52) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL2283858 | 0.97 | — | — | |
| SCHEMBL290618 | 0.92 | — | — | |
| SCHEMBL290856 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL15398546 | 0.82 | — | — | |
| SCHEMBL302071 | 0.82 | ALDH1A1 (0.39) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL4874234 | 0.82 | ALDH1A1 (0.39) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL22444527 | 0.82 | ALDH1A1 (0.39) | USP2ALDH1A1LMNACYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482339-B2 | 2-Naphthylimino-1,3-thiazine derivative | SHIONOGI AND CO., LTD. (JP) | 2009-01-27 | — | — | US | disclosed |
| US-20080146612-A1 | Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor | ASTRAZENECA AB (SE) | 2008-06-19 | — | — | US | disclosed |
| EP-1844003-A1 | NOVEL BIAROMATIC COMPOUNDS, INHIBITORS OF THE P2X7-RECEPTOR | AstraZeneca AB (SE) | 2007-10-17 | — | — | EP | disclosed |
| US-20060281738-A1 | 2-Naphthylimino-1,3-thiazine derivative | SHIONOGI AND CO., LTD. (JP) | 2006-12-14 | — | — | US | disclosed |
| WO-2006080884-A1 | NOVEL BIAROMATIC COMPOUNDS, INHIBITORS OF THE P2X7-RECEPTOR | ASTRAZENECA AB (SE) | 2006-08-03 | — | — | WO | disclosed |
| EP-1659117-A1 | 2-NAPHTHYLIMINO-1,3-THIAZINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2006-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146612-A1 | Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor | P2RX2, P2RX1, ADORA1 | USP2 4230/4885ALDH1A1 719/4885LMNA 3293/4885 |
| US-20060281738-A1 | 2-Naphthylimino-1,3-thiazine derivative | NPM1, OXTR, CYP2S1 | USP2 4442/4885ALDH1A1 1571/4885LMNA 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.